Oral corticosteroid-sparing effects of mepolizumab in severe eosinophilic asthma: evidence from randomized controlled trials and real-world studies.
- DOI
- 10.1177/17534666221107313
- Published
- 2022 Jan-Dec
- Container
- Therapeutic advances in respiratory disease
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1177/17534666221107313,
title = {Oral corticosteroid-sparing effects of mepolizumab in severe eosinophilic asthma: evidence from randomized controlled trials and real-world studies.},
author = {Casale TB and Burnette A and Bourdin A and Howarth P and Hahn B and Stach-Klysh A and Khurana S},
year = {2022},
journal = {Therapeutic advances in respiratory disease},
doi = {10.1177/17534666221107313},
url = {https://doi.org/10.1177/17534666221107313}
}RIS
TY - JOUR TI - Oral corticosteroid-sparing effects of mepolizumab in severe eosinophilic asthma: evidence from randomized controlled trials and real-world studies. AU - Casale TB AU - Burnette A AU - Bourdin A AU - Howarth P AU - Hahn B AU - Stach-Klysh A AU - Khurana S PY - 2022 JO - Therapeutic advances in respiratory disease DO - 10.1177/17534666221107313 UR - https://doi.org/10.1177/17534666221107313 ER -
APA
TB, C., A, B., A, B., P, H., B, H., A, S., & S, K. (2022). Oral corticosteroid-sparing effects of mepolizumab in severe eosinophilic asthma: evidence from randomized controlled trials and real-world studies.. Therapeutic advances in respiratory disease. https://doi.org/10.1177/17534666221107313
Source records
- pubmed · retrieved 2026-09-26T07:51:44.486Z